EPIX Pharmaceuticals, a US biopharmaceutical company focused on discovering and developing therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, says that its novel blood pool magnetic resonance angiography agent, Vasovist (gadofosveset trisodium) has been approved for marketing in South Korea.
This is the 34th country (including all 27 members of the European Union, Switzerland, Turkey, Australia and Canada) outside the USA where this agent has been approved for marketing, said the firm's chief executive, Michael Kauffman. "We remain hopeful for approval of Vasovist in the USA by the end of 2008 and, as previously-announced, recently resubmitted a New Drug Application for Vasovist to the US Food and Drug Administration," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze